Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from JNJ

San Francisco To Start Opioid Epidemic Trial Against Teva, Walgreen: Reuters

San Francisco will start a trial against Walgreens Boots Alliance Inc (NASDAQ:WBA) and three other companies accused of fueling an opioid crisis in the city. San Francisco has alleged that Walgreens, Teva Pharmaceutical Industries Ltd (NYSE:TEVA), AbbVie Inc's (NYSE:ABBV) Allergan unit, and Teva-owned Anda Inc created a "public nuisance" by flooding the city with prescription opioids and failing…

Benzinga

President Biden To Outline Strategy To Tackle Drug Addiction, Overdose: Reuters

U.S. President Joe Biden will reveal a new strategy today for dealing with drug addiction and overdoses to expand access to medications for opioid overdoses, increase funding for law enforcement, and expand sanctions against traffickers. According to U.S. Centers For Disease Control And Prevention Data, the U.S. opioid crisis fueled more than…

Benzinga

4 Rock-Solid Dow Jones Stocks to Buy and Hold

Despite volatile market conditions owing to the Russia-Ukraine war, supply chain bottlenecks, high inflation, and imminent aggressive federal interest rate increases, the Dow Jones Industrial Average has managed to advance over the past month on an improving labor market and strong corporate results. So, we think it could be wise…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

JNJ, McKesson, Endo Settle $275M Opioid Claims With Alabama: Reuters

Alabama reached $276 million in settlements with Johnson & Johnson (NYSE:JNJ), McKesson Corporation (NYSE:MCK), and Endo International Plc (NASDAQ:ENDP), resolving claims on the opioid addiction crisis, the state attorney general said. McKesson will pay $141 million. JNJ and Endo will pay $70.3 million and $25 million, respectively, Alabama Attorney General Steve Marshall said in a statement. The three…

Benzinga

Johnson & Johnson Whale Trades For April 20

A whale with a lot of money to spend has taken a noticeably bearish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 11 strange trades.

Benzinga

5 Ultra-Safe Dividend Aristocrats to Buy in a Market Downturn

Worries over intensifying supply disruptions with growing sanctions on Russia have shaken investors. Furthermore, rising crude oil prices coupled with record-high inflation have given rise to recession fears. Thus, we think it could be wise to bet on ultra-safe dividend aristocrats Johnson & Johnson (JNJ), Walmart (WMT), PepsiCo (PEP), Abbott…

StockNews.com

Mid-Afternoon Market Update: Nasdaq Surges 200 Points; Dentsply Sirona Shares Plunge

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Mid-Day Market Update: Crude Oil Down Over 5%; Checkmate Pharmaceuticals Shares Spike Higher

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Tuesday.

Benzinga

BeiGene Shares Updated Data From Tislelizumab Combo Trial In Head & Neck Cancer

BeiGene Ltd (NASDAQ:BGNE) shared updated data analyses from the Phase 3 RATIONALE-309 trial of tislelizumab combined with chemotherapy versus chemotherapy plus placebo in first-line recurrent or metastatic nasopharyngeal cancer. Updated efficacy analyses showed that, at a median follow-up of 15.5 months, tislelizumab/chemotherapy combo demonstrated a clinically significant progression-free survival (PFS) benefit over chemotherapy…

Benzinga

Mid-Morning Market Update: Markets Open Higher; Dow Jumps 400 Points

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 400 points on Tuesday.

Benzinga

Johnson & Johnson Suspends Sales Forecast For COVID-19 Vaccine, Trims FY22 Profit Outlook

Johnson & Johnson (NYSE:JNJ) has reported Q1 FY22 adjusted earnings of $2.67 per share, up 3.1% Y/Y and ahead of the consensus of $2.61. Net sales increased 5% Y/Y (7.9% on an operational basis) to $23.43 billion, missing the consensus of $23.67 billion. Pharmaceuticals contributed $12.87 billion in sales, +9.3%, due to Darzalex…

Benzinga

Recap: Johnson & Johnson Q1 Earnings

Johnson & Johnson (NYSE:JNJ) reported its Q1 earnings results on Tuesday, April 19, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Benzinga

Earnings Outlook For Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) is set to give its latest quarterly earnings report on Tuesday, 2022-04-19. Here's what investors need to know before the announcement. Analysts estimate that Johnson & Johnson will report an earnings per share (EPS) of $2.61.

Benzinga

Raymond James Thinks Med Tech Investors are Somewhat 'Paralyzed' Ahead Of Q1 Earnings

Raymond James has outlined its expectations for next week when Johnson & Johnson (NYSE:JNJ), Abbott Laboratories (NYSE:ABT), and Intuitive Surgical Inc (NASDAQ:ISRG) will report Q1 FY22 earnings. Analysts believe that the Med Tech investors have become somewhat 'paralyzed' given the macro/factor-driven concerns. On the macro, investor attention seems to be focused less on revenue growth and more…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

What 6 Analyst Ratings Have To Say About Johnson & Johnson

Analysts have provided the following ratings for Johnson & Johnson (NYSE:JNJ) within the last quarter:

StockNews.com

5 Global Healthcare Stocks to Buy as BofA Warns of a "Recession Shock"

The healthcare industry is well-positioned to ride out a potential recessionary shock, thanks in-part to the inelastic demand for COVID-19 vaccines worldwide. Thus, we think investors could invest in fundamentally sound healthcare stocks Pfizer Inc. (PFE), Johnson & Johnson (JNJ), AbbVie Inc. (ABBV), Eli Lilly and Company (LLY), and Merck…

StockNews.com

5 Top Mega-Cap Stocks in the Healthcare Sector to Buy This Month

The healthcare sector is known for its defensive qualities. Therefore, betting on mega-cap healthcare stocks could be one of the best ways to generate stable returns amid the current, extended, market volatility. We think their solid growth attributes and profit margins make the stocks of Novartis (NVS), Danaher (DHR), Eli…

Benzinga

MindMed Appoints Francois Lilienthal As New CCO

With over twenty years of experience in the biopharmaceutical industry, Francois Lilienthal, MD, has joined Mind Medicine Inc. (NASDAQ:MNMD) as chief commercial officer (CCO). He had been serving as a consultant for the company for the last six months. Lilienthal has a long trajectory with pharmaceutical companies—in 1997, he was…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

West Virginia Says J&J, Teva, AbbVie Caused 'Tsunami' Of Opioid Addiction: Reuters

West Virginia's attorney general urged a judge to hold Johnson & Johnson (NYSE: JNJ), Teva Pharmaceuticals Industries Ltd (NYSE: TEVA), and AbbVie Inc's (NYSE:

StockNews.com

5 Healthcare Stocks Likely to Withstand a Recession

The healthcare industry has attracted massive investor interest since the onset of the COVID-19 pandemic and could remain in the limelight as COVID cases surge again and necessitate the need for more COVID shots. In addition, the healthcare sector is known to withstand recessions relatively well. So, with several analysts…

StockNews.com

5 Brand-Name Dividend Stocks to Grab Right Now

The stock market is expected to remain under pressure in the near term, given rising concerns over inflation, deepening supply chain disruptions, and the potential for aggressive central bank interest rate increases. For investors seeking ways to dodge market volatility and generate stable returns, we think it could be wise…

StockNews.com

AstraZeneca vs. Johnson & Johnson: Which Drug Manufacturer is a Better Buy?

The COVID-19 pandemic has boosted the revenues of most drug manufacturers. And since healthcare expenditure has been climbing steadily, and because the global population is aging, the demand for medicines is expected to grow. Quality drug manufacturers AstraZeneca (AZN) and Johnson & Johnson (JNJ) should benefit from this trend. But…

Benzinga

Protagonist Therapeutics Earns $25M Milestone Payment From Janssen Biotech

Protagonist Therapeutics (NASDAQ:PTGX) has received a $25 million milestone payment from its collaboration with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE:JNJ). The payment comes after the dosing of the third patient in the Phase 2b FRONTIER 1 clinical trial of PN-235 (JNJ-77242113). FRONTIER 1 is a Phase 2b dose-ranging study to evaluate the…

Benzinga

Expert Ratings For Johnson & Johnson

Johnson & Johnson (NYSE:JNJ) has observed the following analyst ratings within the last quarter:

Benzinga

What Are Whales Doing With Johnson & Johnson

A whale with a lot of money to spend has taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson (NYSE:JNJ) we detected 21 strange trades.

1 … 13 14 15 16

People

Joe Biden

68,714 stories

Dipanjan BanchurSince

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.